Adicet Bio, Inc. Operating Lease, Payments, Use
Adicet Bio, Inc. (ACET) reported Operating Lease, Payments, Use of $773.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePaymentsUse · last filed 2023-11-08
- Adicet Bio, Inc. operating lease, payments, use for the quarter ending 2023-09-30 was $773.00K, a 15.55% increase year-over-year.
- Adicet Bio, Inc. operating lease, payments, use for the quarter ending 2023-06-30 was $1.62M, a 313.81% increase year-over-year.
- Adicet Bio, Inc. operating lease, payments, use for the quarter ending 2023-03-31 was $2.47M, a 384.15% increase year-over-year.
- Adicet Bio, Inc. operating lease, payments, use for the quarter ending 2022-12-31 was $693.00K.
- Adicet Bio, Inc. operating lease, payments, use for fiscal 2022 was $2.26M, a 343.05% increase from fiscal 2021.
- Adicet Bio, Inc. operating lease, payments, use for fiscal 2021 was $511.00K, a 40.51% decline from fiscal 2020.
- Adicet Bio, Inc. operating lease, payments, use for fiscal 2020 was $859.00K.
| Period end | Operating Lease, Payments, Use 3 month | Operating Lease, Payments, Use 6 month | Operating Lease, Payments, Use 9 month | Operating Lease, Payments, Use 12 month |
|---|---|---|---|---|
| 2023-09-30 | $773.00K 10-Q · filed 2023-11-08 | $2.39M derived: sum of 2 quarters · filed 2023-11-08 | $4.87M derived: sum of 3 quarters · filed 2023-11-08 | $5.56M derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | $1.62M 10-Q · filed 2023-08-09 | $4.09M derived: sum of 2 quarters · filed 2023-08-09 | $4.79M derived: sum of 3 quarters · filed 2023-08-09 | $5.45M derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | $2.47M 10-Q · filed 2023-05-09 | $3.17M derived: sum of 2 quarters · filed 2023-05-09 | $3.84M derived: sum of 3 quarters · filed 2023-05-09 | $4.23M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $693.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.36M derived: sum of 2 quarters · filed 2023-03-15 | $1.75M derived: sum of 3 quarters · filed 2023-03-15 | $2.26M 10-K · filed 2023-03-15 |
| 2022-09-30 | $669.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.06M derived: sum of 2 quarters · filed 2022-11-08 | $1.57M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $391.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $902.00K 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | $511.00K 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $511.00K 10-K · filed 2023-03-15 | |||
| 2020-12-31 | $859.00K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |